Transaction DateRecipientSharesTypePriceValue
20th August 2020Joseph Walter Vazzano3,840Open or private sale$12.13$46,579.20
14th July 2020Neil Herskowitz16,611Grant/award etc.$0.00
16th June 2020Jay D Kranzler10,000Grant/award etc.$0.00
16th June 2020Neil Herskowitz10,000Grant/award etc.$0.00
5th June 2020Neil Herskowitz24,390Grant/award etc.$0.00
10th March 2020Joseph Walter Vazzano1,889Open or private purchase$7.94$14,998.66
9th March 2020Joseph Walter Vazzano1,400Open or private purchase$7.99$11,186.00
9th March 2020Joseph Walter Vazzano100Open or private purchase$7.97$797.00
27th February 2020Neil Herskowitz2,400Open or private purchase$8.20$19,680.00
26th February 2020Neil Herskowitz161Open or private purchase$8.73$1,405.53
Avenue Therapeutics
Avenue Therapeutics logo

Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 9/10.

Avenue Therapeutics, Inc. engages in acquiring, licensing, developing, and commercializing products for use in the intensive care hospital setting. It focuses on the development of intravenous tramadol, which is intended for the treatment of moderate to moderately severe post-operative pain. The company was founded in 2015 and is headquartered in New York, NY.

Ticker: ATXI
Sector: Health Technology
Industry: Pharmaceuticals: Major
SEC Central Index Key (CIK): 1644963
Employees: 4
Exchange: NASDAQ
Auditor Opinion:

Disclosure Language changes
Red Flags